14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women
Key Takeaways
Diabetes mellitus is diagnosed per ADA criteria by fasting plasma glucose (FPG) ≥ 126 mg/dL, 2-hour 75g OGTT ≥ 200 mg/dL, A1C ≥ 6.5%, or random plasma glucose ≥ 200 mg/dL with classic hyperglycemic symptoms; in asymptomatic patients, diagnosis requires two abnormal results from the same sample or two separate test samples.
Prediabetes thresholds comprise FPG 100–125 mg/dL (impaired fasting glucose), 2-hour OGTT 140–199 mg/dL (impaired glucose tolerance), or A1C 5.7%–6.4%, identifying women at high risk for progression to overt diabetes and cardiovascular disease.
Metabolic syndrome is defined by NCEP ATP III criteria as ≥ 3 of 5 markers: waist circumference >35 inches in women, triglycerides ≥ 150 mg/dL, HDL-C <50 mg/dL in women, blood pressure ≥ 130/85 mmHg, and fasting glucose ≥ 100 mg/dL, closely clustering with polycystic ovary syndrome (PCOS).
Individualized glycemic targets in non-pregnant adult women range from A1C <7.0% for most adults, to stringent <6.5% for young newly diagnosed women without cardiovascular disease, and relaxed <8.0% for patients with advanced vascular complications, extensive comorbidities, or severe hypoglycemia history.
Metformin is the foundational first-line biguanide (contraindicated if eGFR <30 mL/min/1.73 m²; hold for iodinated contrast); GLP-1 receptor agonists and SGLT2 inhibitors provide cardiorenal protection and weight reduction, though GLP-1 RAs require discontinuation ≥ 2 months prior to planned conception and SGLT2 inhibitors increase risks of mycotic vulvovaginitis and euglycemic DKA.
Diagnostic Criteria for Diabetes Mellitus & Prediabetes
Type 2 diabetes mellitus (T2DM) arises from progressive beta-cell insulin secretory defects on a background of peripheral insulin resistance. In women, hormonal transitions across the reproductive lifespan—including polycystic ovary syndrome (PCOS), gestational diabetes mellitus (GDM), and menopause—powerfully modulate insulin sensitivity. Clinical practice guidelines from the American Diabetes Association (ADA) Standards of Care mandate rigorous biochemical thresholds to establish a formal diagnosis.
ADA Diagnostic Thresholds for Overt Diabetes Mellitus
A diagnosis of overt diabetes mellitus is confirmed when any one of the following criteria is met:
- Fasting Plasma Glucose (FPG): ≥ 126 mg/dL (7.0 mmol/L), with fasting defined as no caloric intake for at least 8 hours.
- 2-Hour Oral Glucose Tolerance Test (OGTT): ≥ 200 mg/dL (11.1 mmol/L) following a 75-gram anhydrous glucose load.
- Glycated Hemoglobin (A1C): ≥ 6.5% (48 mmol/mol), using an NGSP-certified, DCCT-standardized laboratory assay.
- Random Plasma Glucose: ≥ 200 mg/dL (11.1 mmol/L) in a patient with classic symptoms of hyperglycemia (polyuria, polydipsia, unexplained weight loss) or in hyperglycemic crisis.
Important
In the absence of unequivocal symptomatic hyperglycemia, diagnosis requires two abnormal test results from either the same blood sample (e.g., FPG ≥ 126 mg/dL and A1C ≥ 6.5% drawn together) or two separate samples collected on different days. If results are discordant, repeat the test that exceeded the diagnostic cutoff.
Prediabetes Classification & Routine Screening
Prediabetes identifies individuals at high risk for progression to overt diabetes and cardiovascular disease:
- Impaired Fasting Glucose (IFG): FPG 100 to 125 mg/dL (5.6 to 6.9 mmol/L).
- Impaired Glucose Tolerance (IGT): 2-hour 75g OGTT 140 to 199 mg/dL (7.8 to 11.0 mmol/L).
- Elevated Glycated Hemoglobin: A1C 5.7% to 6.4% (39 to 47 mmol/mol).
Screening for prediabetes and T2DM initiates at age 35 for all asymptomatic adults and repeats every 3 years. Screen earlier in women of any age with overweight or obesity (BMI ≥ 25 kg/m², or ≥ 23 kg/m² in Asian Americans) having ≥ 1 additional risk factor: first-degree relative with diabetes, high-risk ethnicity, GDM history, physical inactivity, hypertension (≥ 130/80 mmHg or on therapy), HDL-C <35 mg/dL, triglycerides >250 mg/dL, or PCOS.
| Glycemic Category | Fasting Plasma Glucose (FPG) | 2-Hour 75g OGTT | Glycated Hemoglobin (A1C) |
|---|---|---|---|
| Normal | <100 mg/dL (5.6 mmol/L) | <140 mg/dL (7.8 mmol/L) | <5.7% (39 mmol/mol) |
| Prediabetes | 100–125 mg/dL (5.6–6.9 mmol/L) | 140–199 mg/dL (7.8–11.0 mmol/L) | 5.7%–6.4% (39–47 mmol/mol) |
| Diabetes Mellitus | ≥ 126 mg/dL (7.0 mmol/L) | ≥ 200 mg/dL (11.1 mmol/L) | ≥ 6.5% (48 mmol/mol) |
Metabolic Syndrome in Women: NCEP ATP III Criteria & Pathophysiology
Metabolic syndrome encompasses a cluster of interrelated vascular and metabolic derangements that elevate cardiovascular mortality two-fold and T2DM risk five-fold. In women, its prevalence escalates sharply following menopause due to estrogen decline and visceral fat redistribution.
NCEP ATP III Diagnostic Criteria
Metabolic syndrome is diagnosed when a woman meets at least 3 of the following 5 criteria:
- Abdominal Obesity: Waist circumference >35 inches (88 cm) in females (>40 inches / 102 cm in males; >31.5 inches / 80 cm in Asian females).
- Elevated Triglycerides: Serum triglycerides ≥ 150 mg/dL (1.7 mmol/L), or on specific drug therapy.
- Reduced HDL Cholesterol: Serum HDL-C <50 mg/dL (1.3 mmol/L) in females (<40 mg/dL in males), or on specific drug therapy.
- Elevated Blood Pressure: Systolic BP ≥ 130 mmHg and/or diastolic BP ≥ 85 mmHg, or on antihypertensive therapy.
- Elevated Fasting Glucose: Fasting plasma glucose ≥ 100 mg/dL (5.6 mmol/L), or on pharmacotherapy for elevated glucose.
Female Pathophysiology & PCOS Interplay
Visceral adipocytes hypersecrete free fatty acids into portal circulation, promoting hepatic insulin resistance and steatosis (MASLD). Concurrently, visceral fat produces inflammatory cytokines (TNF-α, IL-6) while suppressing protective adiponectin. In reproductive-age women, compensatory hyperinsulinemia stimulates ovarian theca cells to overproduce androgens and suppresses hepatic SHBG, accelerating the phenotypic triad of PCOS: hyperandrogenism, chronic anovulation, and metabolic dysfunction.
Individualized Glycemic Targets in Non-Pregnant Women
Glycemic targets balance microvascular protection against hypoglycemia hazards:
- General Adult Target: A1C <7.0% (53 mmol/mol), corresponding to an estimated average glucose (eAG) of ~154 mg/dL. Preprandial capillary glucose target is 80 to 130 mg/dL (4.4 to 7.2 mmol/L); peak postprandial capillary glucose target is <180 mg/dL (10.0 mmol/L).
- Stringent Target (A1C <6.5% / 48 mmol/mol): Appropriate for younger women with newly diagnosed T2DM, long life expectancy, no cardiovascular disease, and managed with low-hypoglycemia-risk agents.
- Relaxed Target (A1C <8.0% / 64 mmol/mol): Indicated for patients with severe hypoglycemia history, hypoglycemia unawareness, limited life expectancy, advanced vascular complications, or extensive comorbidities.
Antihyperglycemic Pharmacotherapy
Modern antihyperglycemic selection prioritizes organ-protective agents with proven cardiorenal benefits.
| Drug Class | Representative Agents | Mechanism of Action | Cardiorenal & Weight Effects | Adverse Effects & Key Clinical Warnings |
|---|---|---|---|---|
| Biguanides | Metformin (500–2000 mg/day) | Activates AMPK; decreases hepatic gluconeogenesis; improves insulin sensitivity. | Weight neutral; ASCVD event reduction; inexpensive. | GI intolerance (diarrhea, nausea); vitamin B12 deficiency; contraindication: eGFR <30 mL/min/1.73 m²; hold for iodinated radiocontrast. |
| GLP-1 Receptor Agonists | Semaglutide, Dulaglutide, Liraglutide; Dual GIP/GLP-1: Tirzepatide | Incretin mimetics: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying. | Robust weight loss; MACE reduction in ASCVD; slows DKD progression. | Nausea, vomiting, diarrhea, pancreatitis; Black Box Warning: medullary thyroid cancer (MTC) / MEN2; discontinue ≥ 2 months before planned conception. |
| SGLT2 Inhibitors | Empagliflozin, Dapagliflozin, Canagliflozin | Inhibit SGLT2 in renal proximal tubule, promoting glucosuria (~70g/day) and natriuresis. | Reduces heart failure hospitalizations (HFrEF/HFpEF); slows CKD; modest weight/BP reduction. | Mycotic vulvovaginitis; UTIs; volume depletion; euglycemic DKA; hold 3–4 days prior to elective surgery. |
| Sulfonylureas | Glipizide, Glimepiride | Close beta-cell ATP-sensitive K+ channels, stimulating insulin exocytosis. | Rapid glucose lowering; low cost. | Hypoglycemia; weight gain; glipizide preferred in renal impairment. |
| Insulins | Basal (Glargine, Degludec); Prandial (Lispro, Aspart) | Activate insulin receptors, driving cellular glucose uptake and storage. | Unlimited glycemic efficacy; required for severe catabolism or A1C ≥ 10%. | Hypoglycemia; weight gain; injection burden; requires capillary glucose tracking. |
Clinical Administration Pearls
- Metformin Safety & Contrast Protocol: Obtain baseline eGFR before starting metformin. It is contraindicated if eGFR is <30 mL/min/1.73 m²; do not initiate if eGFR is 30–44 mL/min/1.73 m² (or reduce existing dose to maximum 1000 mg/day). In patients with eGFR 30–59 mL/min/1.73 m² undergoing iodinated radiocontrast imaging, hold metformin prior to or at the time of the procedure and withhold for 48 hours afterward, restarting only after confirming stable renal function.
- GLP-1 RAs & Conception: Injectable GLP-1 RAs (such as semaglutide) have prolonged half-lives and must be discontinued at least 2 months prior to planned conception to allow complete drug washout and avoid embryofetal toxicity. Transition patients to insulin or metformin preconception.
- SGLT2 Inhibitors & Euglycemic DKA: Glucosuria promotes vulvovaginal candidiasis in up to 15% of women. Under physiologic stress (fasting, surgery, acute illness), glucosuria reduces insulin demand while glucagon surges, triggering lipolysis and ketogenesis with blood glucose <250 mg/dL (euglycemic DKA).
Tip
Screen women on long-term metformin therapy (>3–4 years) annually for vitamin B12 deficiency, particularly if presenting with paresthesias, neuropathy, or macrocytic anemia. Metformin impairs calcium-dependent ileal absorption of the B12-intrinsic factor complex.
Preventive Microvascular Surveillance & Risk Reduction
Chronic hyperglycemia silently drives microvascular damage requiring structured annual surveillance:
1. Diabetic Retinopathy
Women with T2DM must undergo a dilated eye examination by an optometrist or ophthalmologist at diagnosis and annually thereafter. Retinal capillary microaneurysms, hemorrhages, and neovascularization threaten vision. If one or more annual exams are normal, intervals may be extended to every 2 years.
2. Diabetic Nephropathy (Diabetic Kidney Disease)
Screen annually with a random spot urine albumin-to-creatinine ratio (UACR) and serum creatinine/eGFR starting at diagnosis:
- Normal: UACR <30 mg/g creatinine.
- Moderately Increased Albuminuria (Microalbuminuria): UACR 30 to 299 mg/g creatinine.
- Severely Increased Albuminuria (Macroalbuminuria): UACR ≥ 300 mg/g creatinine.
Persistent albuminuria requires confirmation on at least 2 of 3 specimens collected over a 3- to 6-month period. First-line therapy for non-pregnant patients with confirmed UACR ≥ 30 mg/g is an ACE inhibitor or Angiotensin Receptor Blocker (ARB) titrated to maximum tolerated dose, combined with an SGLT2 inhibitor.
3. Diabetic Peripheral Neuropathy & Comprehensive Foot Exam
Perform an annual foot examination to identify loss of protective sensation (LOPS), peripheral arterial disease, and skin ulceration. LOPS testing requires the 10-gram Semmes-Weinstein monofilament applied at plantar sites, paired with at least one additional sensory test: 128-Hz tuning fork vibration at the hallux, pinprick, temperature perception, or Achilles reflex.
A 44-year-old female presents for a routine well-woman examination. She reports no polyuria, polydipsia, or weight changes. Her past medical history is notable for gestational diabetes mellitus during her second pregnancy 8 years ago. Physical examination reveals a body mass index (BMI) of 31.2 kg/m², waist circumference of 37 inches (94 cm), and blood pressure of 134/86 mmHg. Fasting laboratory evaluation reveals: fasting plasma glucose 118 mg/dL, glycated hemoglobin (A1C) 6.1%, triglycerides 182 mg/dL, and HDL-C 42 mg/dL. What is the most accurate clinical diagnostic assessment and initial management plan for this patient?
Overt Type 2 Diabetes Mellitus; immediately initiate oral metformin 1000 mg twice daily and refer for retinal examination.
Metabolic syndrome and prediabetes; intensive lifestyle change targeting 7% weight loss and 150 minutes of weekly activity.
Normal metabolic profile consistent with age; schedule routine re-evaluation in 3 years.
Isolated hypertriglyceridemia; initiate gemfibrozil 600 mg twice daily and withhold glycemic interventions.
A 31-year-old female with an 8-year history of Type 2 Diabetes Mellitus presents for preconception counseling. Her current medications include oral metformin 1000 mg twice daily and subcutaneous semaglutide 1.0 mg once weekly. Her blood pressure is 122/76 mmHg and her most recent A1C is 6.4%. She and her partner plan to discontinue barrier contraception and attempt conception within the next few months. What is the most appropriate management regarding her antihyperglycemic regimen during this preconception consultation?
Continue both metformin and semaglutide throughout conception and pregnancy, as both provide safe glycemic stability.
Discontinue metformin immediately due to lactic acidosis risk in early pregnancy, but continue semaglutide until a positive pregnancy test occurs.
Discontinue semaglutide at least 2 months prior to attempting conception, continue metformin, and initiate insulin therapy if additional glycemic control is required.
Switch semaglutide to an oral SGLT2 inhibitor such as empagliflozin to minimize embryofetal toxicity during organogenesis.
A 56-year-old female with Type 2 Diabetes Mellitus presents for her annual comprehensive preventive surveillance encounter. Her diabetes is currently managed with metformin and glimepiride; her A1C is 7.4% and blood pressure is 138/84 mmHg. Laboratory testing demonstrates an estimated GFR of 84 mL/min/1.73 m² and a random spot urine albumin-to-creatinine ratio (UACR) of 142 mg/g creatinine. A repeat spot UACR performed 6 weeks later confirms persistence at 158 mg/g. Which clinical action represents the most appropriate evidence-based intervention to protect this patient from progressive renal disease?
Initiate an ACE inhibitor or Angiotensin Receptor Blocker (ARB) and titrate to the maximum tolerated dose.
Reassure the patient that albuminuria below 300 mg/g is benign and recheck her urine in 12 months.
Discontinue metformin immediately and initiate daily loop diuretic therapy with furosemide.
Refer the patient for urgent diagnostic renal biopsy to evaluate for nondiabetic glomerulonephritis.
Sections you finish are checked off in the contents.